Conflict of Interest
Johnson & Johnson), Johnson & Johnson, Bayer, Astellas, Janssen R&D
Kim N. Chi is a consultant for and has received honoraria and research funding from Astellas, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, and Sanofi. Jason Hafron reported receipt of consulting/advisory fees, honoraria, and research funding from Astellas Pharma Inc., Amgen Inc., Janssen Biotech Inc., Lantheus, H. Merck & Co. Inc., Myovant Sciences Inc., Procept-Biorobotic; H, Progenics Pharmaceuticals, Inc.; honoraria from Bayer, Dendreon Pharmaceuticals LLC, Tolmar Pharmaceuticals Inc.; honoraria and research funding from Blue Earth Diagnostics, miR Scientific Inc., and Promaxo; research funding from Myriad Genetics Inc., consulting/advisory and honoraria from Pfizer Inc., Urogen Pharma Inc.; and consultant/advisor to Lynx DX. Peter De Porre is an employee of Janssen Pharma (Johnson & Johnson). Raymond Scott Maul is an employee of Janssen R&D and has ownership interest in Johnson & Johnson. Ronald Tutrone reported research funding from Janssen, Merck, Johnson & Johnson, Bayer, Astellas, Lilly, and Very. The other authors indicated no financial relationships.